Physician profile
Martha Rey Saunders
NPI 1316922388
$288,375.64
in general payments reported to CMS, 2019-2025
5 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $22K · 2021: $27K · 2022: $31K · 2023: $34K · 2024: $31K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $121K · Royalty Or License: $65K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $120,598.14 |
| Royalty Or License | $64,554.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pediatric Alliance LLC | $288,331.14 | 2019-2025 | |
| Shire North American Group INC | $32.09 | 2019 | |
| Biogen, INC. | $12.41 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$538,655.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.